Advances in immunotherapy for triple-negative breast cancer

Molecular Cancer

Review

Peng Qiu¹  Jingying Li²  Jiawen Bu³  Yang Liu³  Yueting Hu³  Zhenyong Zhang³  Jinqi Xue³  Xi Gu³  Jiang Yi³ 

[1] Department of Anesthesiology, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning Province, China;Department of Health Management, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning Province, China;Department of Oncology, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning Province, China;

关键词: Triple-negative breast cancer;    Immunotherapy;    Immune checkpoint;    Drug resistance;    Tumor microenvironment;   

DOI  :  10.1186/s12943-023-01850-7

 received in 2023-04-15, accepted in 2023-08-26,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundImmunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor cells and increases the tumoricidal effect of immune cells. It also suppresses immunosuppressive molecules, activates or restores immune system function, enhances anti-tumor immune responses, and inhibits the growth f tumor cell. This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC).Main bodyImmunotherapy approaches for TNBC have been diversified in recent years, with breakthroughs in the treatment of this entity. Research on immune checkpoint inhibitors (ICIs) has made it possible to identify different molecular subtypes and formulate individualized immunotherapy schedules. This review highlights the unique tumor microenvironment of TNBC and integrates and analyzes the advances in ICI therapy. It also discusses strategies for the combination of ICIs with chemotherapy, radiation therapy, targeted therapy, and emerging treatment methods such as nanotechnology, ribonucleic acid vaccines, and gene therapy. Currently, numerous ongoing or completed clinical trials are exploring the utilization of immunotherapy in conjunction with existing treatment modalities for TNBC. The objective of these investigations is to assess the effectiveness of various combined immunotherapy approaches and determine the most effective treatment regimens for patients with TNBC.ConclusionThis review provides insights into the approaches used to overcome drug resistance in immunotherapy, and explores the directions of immunotherapy development in the treatment of TNBC.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

41408_2023_919_Article_IEq13.gif

Fig. 2

13690_2023_1177_Figb_HTML.png

Fig. 3